Sodium-glucose cotransporter 2 inhibitors are associated with modest increases in haemoglobin and haematocrit levels, according to a meta-analysis of 85 randomised clinical trials published in JAMA. The study examined 70,543 participants across trials with a median follow-up of 24 weeks, providing a quantitative assessment of markers related to red blood cell production.
Plain English: What These Red Blood Cell Changes Mean for Patients
- Higher Counts: Patients taking SGLT2 inhibitors showed an average increase of 0.55 g/dL in haemoglobin and a 2.17% rise in haematocrit compared to baseline.
- Hormonal Shifts: Erythropoietin, the hormone that stimulates red blood cell production, increased by 2.35 mIU/mL in the treatment group.
- Unclear Impact: Although these changes are statistically significant, researchers emphasize that their direct clinical importance for everyday patient health remains uncertain.
Meta-Analysis Reveals Broad Shifts Across 85 Clinical Trials
Led by researchers investigating the physiological impacts of SGLT2 inhibitors, the systematic review pooled data from 70,543 participants suffering from cardiovascular disease, diabetes, heart failure, or chronic kidney disease. Investigators searched PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials through July 22, 2026. Eligible studies comprised randomised, double-masked clinical trials comparing SGLT2 inhibitors against either placebo or active comparators.
Out of the 85 evaluated trials, 78 used a placebo control, while seven relied on active comparators such as sitagliptin. The primary outcomes tracked distinct physiological alterations between the treatment and control arms. Haemoglobin rose by 0.55 g/dL from baseline among participants receiving SGLT2 inhibitors, contrasting with a 0.08 g/dL decrease in control cohorts. This yielded a significant between-group difference of 0.60 g/dL with a 95% confidence interval ranging from 0.55 to 0.66 and a p-value below 0.001.
Haematocrit levels followed a parallel trajectory. Participants on SGLT2 inhibitors experienced a 2.17% increase, whereas control participants registered a minor shift of −0.13%. The resulting between-group difference reached 2.36% with a 95% confidence interval between 2.19–2.52 and a p<0.001. Secondary outcomes similarly reflected alterations in iron metabolism and erythropoiesis.
Erythropoietin Rise and Iron Metabolism Alterations
Beyond basic red blood cell counts, the secondary outcomes mapped distinct shifts in iron regulation and hormonal triggers. Erythropoietin climbed by 2.35 mIU/mL in individuals treated with SGLT2 inhibitors, compared to just 0.04 mIU/mL in control participants. This produced a statistically significant between-group difference of 2.11 mIU/mL.
Concurrently, markers of iron storage and transport displayed measurable declines. Transferrin saturation decreased by 2.2% in the treatment group against a 0.10% drop in controls, leading to a between-group difference of −0.84%. Four of the six secondary outcomes analyzed demonstrated clear statistical associations with SGLT2 inhibitor administration.
Despite these clear biochemical shifts, the clinical significance of the findings remains an open question. The analysis confirmed that SGLT2 inhibitors alter haemoglobin, haematocrit, erythropoietin, and transferrin saturation, but it did not establish whether these alterations translate into tangible clinical benefits or risks for patients managing chronic conditions.
Future Investigation Required for Long-Term Implications
The research underscores a pressing need for dedicated follow-up studies to clarify why these haematological changes occur and how they affect long-term patient prognoses. While the statistical power of the 85 pooled trials establishes a clear link between SGLT2 inhibitors and elevated markers of red blood cell production, further clinical trials are necessary to determine the precise downstream consequences for vulnerable populations.
References
- Yang Y et al. Sodium-glucose cotransporter 2 inhibitor use and levels of hemoglobin, markers of iron metabolism, and erythropoiesis: a systematic review and meta-analysis of randomized clinical trials. JAMA. 2026; doi: 10.1001/jama.2026.19921.
